Krystal Biotech Inc

NASDAQ:KRYS   3:59:59 PM EDT
77.85
-1.45 (-1.83%)
Products

Krystal Biotech Receives FDA Acceptance Of KB407 IND Application For Cystic Fibrosis Clinical Trial

Published: 08/01/2022 12:07 GMT
Krystal Biotech Inc (KRYS) - Krystal Biotech Receives FDA Acceptance of Kb407 Ind Application for Cystic Fibrosis Clinical Trial.
Krystal Biotech Inc - Anticipates Initiating Clinical Trial in 2h 2022.